We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Bio-Rad and Infometrix to Release KnowItAll Metabolomics Software Solution

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Bio-Rad Laboratories Inc. and Infometrix have announced plans to release the KnowItAll® Informatics System, Metabolomics Edition, integrating Infometrix' Pirouette® chemometrics technology with Bio-Rad's award-winning KnowItAll® platform, databases and NMR (Nuclear Magnetic Resonance) tools.

"The KnowItAll® Metabolomics Edition leverages Bio-Rad's rich history of spectroscopic and cheminformatics technologies with our recent successes in the ADME/Tox market," said Gregory M. Banik, Ph.D., Bio-Rad's Informatics Division General Manager.

"We look forward to continued development of state-of-the-art tools to facilitate research in metabolomics and metabonomics."

In addition to the Infometrix tools for multivariate data analysis, the KnowItAll® Metabolomics Edition incorporates Bio-Rad's patent-pending Overlap Density Heatmap technology for comparative spectral visualization.

The product also includes a database of NMR spectra of common metabolites with Internet links to the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, a prominent bioinformatics resource of metabolic pathways.

The integration of these technologies will allow researchers performing metabolic profiling studies to easily manage and analyze data in their search for relevant biomarkers, which can be used to distinguish normal versus abnormal biological systems and response to drug treatment.

"The combination of Infometrix' Pirouette® chemometrics technology with Bio-Rad's KnowItAll® Informatics System offers important solutions for drug discovery researchers and for the future of metabolomics," said Brian Rohrback, Ph.D., President of Infometrix.